Skip to main content

Table 2 Summary measures and comparison of baseline patient characteristics between the different C1M, C3M and RF subgroups

From: Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis

  All C1ML C1MH C1MV C3ML C3MH C3MV RFL RFH RFV CRPL CRPH CRPV
N 474 237 237 118 237 237 118 94 380 198 240 234 118
Gender (%)   87.8 79.7* 74.6** 84.0 83.5 83.1 84.0 83.7 84.0 87.1 80.3* 77.1*
Age, years   53.8 (12.1) 53.7 (12.6) 54.1 (13.0) 53.8 (12.2) 53.4 (12.5) 53.2 (11.2) 54.9 (12.7) 53.4 (12.2) 54.4 (11.5) 53.7 (12.2) 53.8 (12.5) 54.0 (12.2)
BMI, kg/cm2 28.2 (6.3) 27.9 (6.2) 28.6 (6.4) 28.8 (6.6) 27.9 (6.1) 28.6 (6.4) 28.9 (6.0)* 28.7 (7.1) 28.1 (6.1) 28.2 (5.8) 27.9 (6.1) 28.5 (6.5) 28.6 (6.8)
Disease duration, years 8.6 (8.2) 8.9 (8.8) 8.4 (7.7)* 8.0 (7.3) 8.1 (8.5) 9.2 (7.9)* 9.2 (8.0)* 7.2 (8.9) 9.0 (8.0)** 9.7 (7.4)**** 8.3 (8.3) 9.0 (8.1) 8.7 (7.4)
C1M, nmol/mL 103 (80) 47 (16) 159 (779)**** 216 (76)**** 72 (49) 134 (92)**** 157 (103)**** 96 (84) 105 (79) 106 (79) 56 (25) 150 (88)**** 193 (94)****
C3M, nmol/mL 34.1 (15) 29.7 (12.5) 38.4 (15.9)**** 42.4 (15.2)**** 23.6 (4.6) 44.6 (14.3)**** 53.7 (15.6)**** 27.7 (10.7) 35.6 (15.4)*** 40.9 (17.8)**** 28.3 (10.3) 39.9 (16.7)**** 44.4 (18.4)****
RF, Units/mL 230 (400) 226 (370) 233 (428)**** 263 (497) 117 (174) 342 (515)**** 489 (651)**** 10 (4) 284 (430)**** 494 (514)**** 153 (228) 308 (509)**** 356 (579)****
CRP, mg/dL 15.6 (21.1) 6.1 (8.8) 25.0 (25.2)**** 39.0 (29.0)**** 8.5 (10.6) 22.6 (26.1)**** 30.9 (31.0)**** 12.2 (19.2) 16.4 (21.5)** 18.7 (22.3)**** 3.8 (2.3) 27.9 (24.7)**** 42.9 (27.2)****
DAS 5.7 (0.9) 5.4 (0.8) 6.1 (0.8)**** 6.4 (0.8)**** 5.5 (0.8) 6.0 (0.9)**** 6.2 (0.9)**** 5.6 (0.8) 5.8 (0.9)* 5.9 (1.0)** 5.3 (0.7) 6.2 (0.8)**** 6.5 (0.8)****
SJC28 12.0 (5.5) 11.7 (5.5) 12.3 (5.6)** 13.2 (5.9)* 11.1 (5.0) 12.9 (5.9)** 13.2 (5.9)** 11.0 (5.3) 12.2 (5.6)* 12.7 (6.0) 11.2 (5.2) 12.9 (5.8)** 13.1 (5.8)**
TJC28 15.7 (6.2) 15.2 (6.0) 16.1 (6.3) 16.8 (6.4)* 15.1 (5.6) 16.2 (6.6) 16.8 (6.8)* 15.1 (6.1) 15.8 (6.2) 16.2 (6.6) 15.0 (5.8) 16.3 (6.5)* 16.7 (6.5)*
HAQ 1.6 (0.6) 1.5 (0.6) 1.6 (0.6)** 1.8 (0.6)**** 1.5 (0.6) 1.6 (0.6)** 1.8 (0.6)*** 1.4 (0.6) 1.6 (0.6)*** 1.7 (0.6)*** 1.4 (5.8) 1.7 (0.6)**** 1.8 (0.6)****
HAQ PAIN 61.2 (19.2) 57.9 (18.0) 64.5 (19.9)* 69.8 (18.0)**** 59.5 (18.1) 62.9 (20.1)* 64.7 (19.7)** 60.1 (19.4) 61.5 (19.2) 62.4 (19.6) 56.5 (18.3) 66.1 (19.0)**** 69.7 (18.6)****
Evaluators global assessment 61.7 (16.1) 59.7 (16.2) 63.8 (15.8)* 67.0 (15.0)*** 59.9 (16.2) 63.6 (15.8)* 64.9 (14.8)* 59.7 (16.6) 62.2 (16.0) 63.9 (14.7) 59.3 (16.2) 64.2 (15.7)** 66.4 (14.8)***
Patients global assessment 60.2 (19.7) 57.1 (18.8) 63.3 (20.1)* 69.2 (17.8)**** 58.3 (18.6) 62.0 (20.6)* 64.6 (19.4)** 60.1 (18.9) 60.2 (19.9) 60.2 (21.1) 55.8 (19.1) 64.7 (19.3)**** 68.4 (19.1)****
MTSS 46.8 (63.2) 42.1 (61.2) 51.4 (64.9)* 58.0 (68.6)** 40.8 (59.3) 52.7 (66.4)* 66.8 (75.6)*** 25.2 (48.7) 52.1 (65.2)**** 62.2 (71.6)**** 35.2 (53.4) 58.6 (70.0)*** 66.3 (69.9)****
JSN 24.0 (30.9) 21.5 (30.0) 26.5 (31.7)* 29.1 (33.0)** 21.0 (29.5) 27.0 (32.0)* 33.7 (35.9)*** 12.9 (23.9) 26.7 (31.8)**** 31.8 (34.4)**** 18.1 (23.3) 30.2 (33.9)**** 33.7 (32.9)****
ERN 22.8 (33.7) 20.6 (32.8) 24.9 (34.5) 28.9 (37.3)* 19.8 (31.0) 25.7 (36.0) 33.1 (41.3)** 12.3 (25.4) 25.3 (35.0)*** 30.4 (39.2)**** 17.2 (28.4) 28.4 (37.6)**** 32.6 (38.6)****
  1. Data is shown as mean (SD) unless otherwise indicated. Mann-Whitney was used to compare the highest subgroups with the low/− (alpha = 0.05), significance levels are indicated by * (p ≤ 0.05), ** (p < 0.01), *** (p < 0.001) and **** (p < 0.0001)